Compare JetBlue Airways Corporation (JBLU) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Medpace Holdings Inc — how do they compare? JetBlue Airways Corporation trades at $5.86 (market cap $2.19B), while Medpace Holdings Inc trades at $599.22 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 7.7× JetBlue Airways Corporation's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| JBLU | MEDP | |
|---|---|---|
Market Cap | $2.19B | $16.90B |
Sector | Industrials | Technology |
52-Week High | $6.46 | $620.59 |
52-Week Low | $4.03 | $393.42 |
Enterprise Value | $9.56B | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.855, up 3.81% today, with a bullish technical signal from moving averages but mixed earnings history including a recent Q2 2026 beat. The company shows negative profitability with a net income margin of -9.32% and ROE of -44.36%, while valuation ratios like P/S of 0.23 suggest potential undervaluation. Recent news highlights analyst downgrades and operational challenges from high fuel costs, alongside strategic initiatives like new fare structures and lounge awards.
Outlook remains cautious due to persistent losses and external pressures, but cost management and revenue growth initiatives offer recovery potential. Key risks include fuel price volatility and competitive intensity, while analyst consensus is neutral with a $5.18 price target slightly below current levels, indicating limited near-term upside amid ongoing fundamental headwinds.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
